<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2208222530
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOVOMIX 30 FLEXPEN 100U\ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN ASPART,INSULIN ASPART PROTAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30,70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        189.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        A10AD05
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NovoMix&reg; 30 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediateacting effect, in the ratio 30/70. Modern insulin products are improved versions of human insulin.<br />NovoMix&reg; 30 is used to reduce the high blood sugar level in adults, adolescents and children aged 10 years and above with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar.<br />NovoMix&reg; 30 will start to lower your blood sugar 10&ndash;20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 24 hours.<br />In treatment of type 2 diabetes mellitus, NovoMix&reg; 30 may be used in combination with tablets for diabetes and/or with injectable antidiabetic products.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use NovoMix&reg; 30<br />► If you are allergic to insulin aspart or any of the other ingredients in this medicine (see section 6, Contents of the pack and other information).<br />► If you suspect hypoglycaemia (low blood sugar) is starting, see a) Summary of serious and very common side effects in section 4.<br />► In insulin infusion pumps.<br />► If FlexPen&reg; is dropped, damaged or crushed.<br />► If it has not been stored correctly or if it has been frozen, see section 5, How to store NovoMix&reg; 30.<br />► If the resuspended insulin does not appear uniformly white, cloudy and aqueous.<br />► If after resuspension, clumps of material are present or if solid white particles stick to the bottom or the wall of the cartridge.<br />If any of these apply, do not use NovoMix&reg; 30. Talk to your doctor, nurse or pharmacist for advice.</p><p>Before using NovoMix&reg; 30<br />► Check the label to make sure it is the right type of insulin.<br />► Always use a new needle for each injection to prevent contamination.<br />► Needles and NovoMix&reg; 30 FlexPen&reg; must not be shared.<br />► NovoMix&reg; 30 FlexPen&reg; is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.</p><p>Warnings and precautions<br />Some conditions and activities can affect your need for insulin. Consult your doctor:<br />► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands.<br />► If you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level.<br />► If you are ill, carry on taking your insulin and consult your doctor.<br />► If you are going abroad, travelling over time zones may affect your insulin needs and the timing hereof.</p><p>Skin changes at the injection site<br />The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3, How to use NovoMix 30).<br />Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.<br />Children and adolescents<br />&bull; NovoMix&reg; 30 can be used in adolescents and children aged 10 years and above.<br />&bull; There is limited experience with NovoMix&reg; 30 in children aged 6&ndash;9 years.<br />&bull; No data are available for NovoMix&reg; 30 in children below 6 years of age.<br />Other medicines and NovoMix&reg; 30<br />Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment.</p><p>Your blood sugar level may fall (hypoglycaemia) if you take:<br />&bull; Other medicines for the treatment of diabetes<br />&bull; Monoamine oxidase inhibitors (MAOI) (used to treat depression)<br />&bull; Beta-blockers (used to treat high blood pressure)<br />&bull; Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)<br />&bull; Salicylates (used to relieve pain and lower fever)<br />&bull; Anabolic steroids (such as testosterone)<br />&bull; Sulfonamides (used to treat infections).<br />Your blood sugar level may rise (hyperglycaemia) if you take:<br />&bull; Oral contraceptives (birth control pills)<br />&bull; Thiazides (used to treat high blood pressure or excessive fluid retention)<br />&bull; Glucocorticoids (such as &lsquo;cortisone&rsquo; used to treat inflammation)<br />&bull; Thyroid hormones (used to treat thyroid gland disorders)<br />&bull; Sympathomimetics (such as epinephrine [adrenaline], salbutamol or terbutaline used to treat asthma)<br />&bull; Growth hormone (medicine for stimulation of skeletal and somatic growth and pronounced influence on the body&rsquo;s metabolic processes)<br />&bull; Danazol (medicine acting on ovulation).</p><p>Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.<br />Beta-blockers (used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar.<br />Thiazolidinediones (class of oral antidiabetic medicines used for the treatment of type 2 diabetes) Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with thiazolidinediones and insulin experienced the development of heart failure. Inform your&nbsp;doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).<br />If you have taken any of the medicines listed here, tell your doctor, nurse or pharmacist.</p><p>Drinking alcohol and taking NovoMix&reg; 30<br />► If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.<br />Pregnancy and breast-feeding<br />► If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. There is limited clinical experience with insulin aspart in pregnancy. Your insulin dose may need to be changed during pregnancy and after delivery.<br />Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.<br />► There are no restrictions on treatment with NovoMix&reg; 30 during breast-feeding.<br />Ask your doctor, nurse or pharmacist for advice before taking any medicine while pregnant or breast-feeding.</p><p><br />Driving and using machines<br />► Please ask your doctor whether you can drive a car or operate a machine:<br />&bull; If you have frequent hypoglycaemia.<br />&bull; If you find it hard to recognise hypoglycaemia.<br />If your blood sugar is low or high, it might affect your concentration and ability to react and therefore also your ability to drive or operate a machine. Bear in mind that you could endanger yourself or others.</p><p><br />Important information about some of the ingredients in NovoMix&reg; 30<br />NovoMix&reg; 30 contains less than 1 mmol sodium (23 mg) per dose, i.e. NovoMix&reg; 30 is essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dose and when to take your insulin<br />Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.<br />NovoMix&reg; 30 is generally taken immediately before a meal. Eat a meal or snack within 10 minutes of the injection to avoid low blood sugar. When necessary, NovoMix&reg; 30 can be given soon after a meal.<br />See How and where to inject, below for information.<br />Do not change your insulin unless your doctor tells you to. If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor.<br />When NovoMix&reg; 30 is used in combination with tablets for diabetes and/or with injectable antidiabetic products your dose may have to be adjusted by your doctor.</p><p><br />Use in children and adolescents<br />NovoMix&reg; 30 can be used in adolescents and children aged 10 years and above when premixed insulin is preferred. Limited clinical data exists for children aged 6&ndash;9 years. No data are available for NovoMix&reg; 30 in children below 6 years of age.</p><p>Use in special patient groups<br />If you have reduced kidney or liver function, or if you are above 65 years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor.</p><p>How and where to inject<br />NovoMix&reg; 30 is for injection under the skin (subcutaneously). Never inject your insulin directly into a vein (intravenously) or muscle (intramuscularly). NovoMix&reg; 30 FlexPen&reg; is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.<br />With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting (see section 4, Possible side effects). The best places to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of<br />your thighs or upper arms. The insulin will work more quickly if you inject around the waist. You should always measure your blood sugar regularly.</p><p>How to handle NovoMix&reg; 30 FlexPen&reg;<br />NovoMix&reg; 30 FlexPen&reg; is a pre-filled, colour-coded, disposable pen containing a mixture of rapidacting and intermediate-acting insulin aspart in the ratio 30/70.<br />Read carefully the instructions for use included in this package leaflet. You must use the pen as described in the Instructions for use.<br />Always ensure you use the correct pen before you inject your insulin.</p><p><br />If you take more insulin than you should<br />If you take too much insulin, your blood sugar gets too low (hypoglycaemia). See a) Summary of serious and very common side effects in section 4.</p><p><br />If you forget to take your insulin<br />If you forget to take your insulin, your blood sugar may get too high (hyperglycaemia). See c) Effects from diabetes in section 4.</p><p><br />If you stop taking your insulin<br />Do not stop taking your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis. See c) Effects from diabetes in section 4.<br />If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />a) Summary of serious and very common side effects<br />Low blood sugar (hypoglycaemia) is a very common side effect. It may affect more than 1 in 10 people.<br />Low blood sugar may occur if you:<br />&bull; Inject too much insulin.<br />&bull; Eat too little or miss a meal.<br />&bull; Exercise more than usual.<br />&bull; Drink alcohol (see Drinking alcohol and taking NovoMix&reg; 30 in section 2).<br />Signs of low blood sugar: Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.<br />Severe low blood sugar can lead to unconsciousness. If prolonged severe low blood sugar is not treated, it can cause brain damage (temporary or permanent) and even death. You may recover more quickly from unconsciousness with an injection of the hormone glucagon given by someone who knows how to use it. If you are given glucagon, you will need glucose or a sugar snack as soon as you&nbsp;are conscious. If you do not respond to glucagon treatment, you will have to be treated in a hospital.</p><p>What to do if you experience low blood sugar:<br />► If you experience low blood sugar, eat glucose tablets or another high sugar snack (e.g. sweets, biscuits, fruit juice). Measure your blood sugar if possible and rest. Always carry glucose tablets or high sugar snacks with you, just in case.<br />► When the symptoms of low blood sugar have disappeared or when your blood sugar level is stabilised, continue insulin treatment as usual.<br />► If you have such low blood sugar that it makes you pass out, if you have had the need for an injection of glucagon, or if you have experienced many incidents of low blood sugar, talk to a doctor. The amount or timing of insulin, food or exercise may need to be adjusted.<br />Tell relevant people that you have diabetes and what the consequences may be, including the risk of passing out (becoming unconscious) due to low blood sugar. Let them know that if you pass out, they must turn you on your side and get medical help straight away. They must not give you any food or drink because you may choke.</p><p>Seek medical advice immediately:<br />&bull; If signs of allergy spread to other parts of your body.<br />&bull; If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heartbeat; feel dizzy.<br />► If you notice any of these signs, seek medical advice immediately.</p><p>Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect less than 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often<br />this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes</p><p>b) List of other side effects<br />Uncommon side effects<br />May affect less than 1 in 100 people.<br />Signs of allergy: Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of taking your insulin. If they do not disappear, see your doctor.</p><p><br />Vision problems: When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary.</p><p><br />Swollen joints: When you start taking insulin, water retention may cause swelling around your ankles and other joints. Normally, this soon disappears. If not, contact your doctor.</p><p><br />Diabetic retinopathy (an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse.<br />Ask your doctor about this.</p><p><br />Rare side effects<br />May affect less than 1 in 1,000 people.</p><p><br />Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain. This is called acute painful neuropathy and is usually transient.</p><p>Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>c) Effects from diabetes<br />High blood sugar (hyperglycaemia) High blood sugar may occur if you:<br />&bull; Have not injected enough insulin.<br />&bull; Forget to take your insulin or stop taking insulin.<br />&bull; Repeatedly take less insulin than you need.<br />&bull; Get an infection and/or a fever.<br />&bull; Eat more than usual.<br />&bull; Exercise less than usual.</p><p><br />Warning signs of high blood sugar:<br />The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed; dry skin; dry mouth and a fruity (acetone) smell of the breath.</p><p><br />What to do if you experience high blood sugar:<br />► If you get any of the above signs: test your blood sugar level, test your urine for ketones if you can, then seek medical advice immediately.<br />► These may be signs of a very serious condition called diabetic ketoacidosis (build-up of acid in<br />the blood because the body is breaking down fat instead of sugar). If you do not treat it, this could lead to diabetic coma and eventually death.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date, which is stated on the FlexPen&reg; label and carton after &lsquo;Expiry&rsquo;. The expiry date refers to the last day of that month.<br />Always keep the pen cap on your FlexPen&reg; when you are not using it, in order to protect it from light.<br />NovoMix&reg; 30 must be protected from excessive heat and light.</p><p><br />Before opening: NovoMix&reg; 30 FlexPen&reg; that is not being used must be stored in the refrigerator at 2&deg;C to 8&deg;C, away from the cooling element. Do not freeze.<br />Before you use NovoMix&reg; 30 FlexPen&reg;, remove it from the refrigerator. It is recommended to resuspend the insulin as instructed every time you use a new pen. See Instructions for use.</p><p><br />During use or when carried as a spare: NovoMix&reg; 30 FlexPen&reg; that is being used or carried as a spare should not be kept in the refrigerator. You can carry it with you and keep it at room temperature (below 30&deg;C) for up to 4 weeks.</p><p><br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is insulin aspart. NovoMix&reg; 30 is a mixture consisting of 30% soluble insulin aspart and 70% insulin aspart crystallised with protamine. 1 ml contains 100 units of insulin aspart. Each pre-filled pen contains 300 units of insulin aspart in 3 ml suspension for<br />injection.</p><p>The other ingredients are glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, protamine sulfate, hydrochloric acid, sodium hydroxide and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NovoMix® 30 is presented as a suspension for injection in a pre-filled pen. The cartridge contains a
glass ball to facilitate resuspension. After resuspension, the liquid should appear uniformly white, cloudy and aqueous.
Do not use the insulin if it does not look uniformly white, cloudy and aqueous after resuspension.
Pack sizes of 5 and 10 pre-filled pens of 3 ml. Not all pack sizes may be marketed.
The suspension is cloudy, white and aqueous.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing authorisation holder:<br />Novo Nordisk A/S<br />Novo All&eacute;<br />DK-2880 Bagsv&aelig;rd<br />Denmark<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March-2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">نوفومِكس<sup>&trade;</sup> 30 هو إنسولين حديث (شبيه الإنسولين) يحتوي على كلٍ من الإنسولين سريع المفعول ومتوسط المفعول، بنسبة 30/70. وتعرف منتجات الإنسولين الحديثة بأنها نسخ محسنة من الإنسولين البشري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم نوفومِكس<sup>&trade;</sup> 30<strong> لخفض مستويات السكر المرتفعة في الدم</strong> للمرضى البالغين والمراهقين والأطفال بدءاً من عمر 10 سنوات المصابين بمرض السكري (السكر). ومرض السكري هو مرض يتسبب في عدم قدرة الجسم على إنتاج الإنسولين الكافي للتحكم في مستوى السكر في الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يبدأ نوفومِكس<sup>&trade;</sup> 30 في خفض نسبة السكر في الدم خلال 10 إلى 20 دقيقة بعد الحقن، ويكون أقصى تأثير له ما بين ساعة و4 ساعات بعد حقنه ويستمر تأثيره لمدة تصل إلى 24 ساعة.</p><p dir="RTL">&nbsp;</p><p>&lrm;أثناء علاج النوع الثاني من داء السكري، يمكن أيضاً استخدام نوفومِكس<sup>&trade;</sup> 30 مع الأدوية المضادة للسكري المتناولة عن طريق الفم و/أو مع المنتجات المضادة للسكري عن طريق الحقن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل نوفومِكس<sup>&trade;</sup></strong><strong> 30</strong> <strong>في الحالات التالية</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية<strong> </strong>للإنسولين أسبارت أو أي مكونات أخرى تدخل في تركيب هذا الدواء (انظر القسم 6، <em>محتويات العبوة ومعلومات أخرى</em>).</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشك في بدء أعراض نقص السكر في الدم (انخفاض مستوى السكر في الدم)، انظر أ) <em>ملخص الآثار الجانبية الخطيرة والشائعة جداً</em> في القسم 4.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في مضخات حقن الإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة سقوط قلم فلكس بن<sup>&trade;</sup> أو تلفه أو كسره.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يتم تخزين الدواء بشكل صحيح أو تم تجميده، انظر القسم 5، <em>كيفية تخزين نوفومِكس<sup>&trade;</sup></em><em> </em><em>30</em>.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الإنسولين &rlm;‫المعلق&rlm;‫ لا يبدو بلون أبيض متجانس غائم ومائي&rlm;‫.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود تكتلات من المواد بعد إعادة &nbsp;التعليق، أو في حالة وجود جزيئيات بيضاء صلبة ملتصقة بالقاع أو جدار الخرطوشة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت أيٌ من هذه الحالات تنطبق عليك، <strong>فلا تستخدم دواء نوفومِكس<sup>&trade;</sup></strong><strong> 30</strong>. استشر طبيبك أو الممرضة أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قبل استعمال نوفومِكس<sup>&trade;</sup></strong><strong> 30</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp; تحقق من الملصق للتأكد من أنه النوع الصحيح من الإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp; استخدم دائماً إبرة جديدة لكل عملية حقن لمنع التلوث.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم &nbsp;&nbsp;مشاركة نفس الإبر ونوفومِكس<sup>&trade;</sup> 30 فلكس بن<sup>&trade;</sup> بين أكثر من شخص.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوفومِكس<sup>&trade;</sup> 30 فلكس بن<sup>&trade;</sup> مناسب فقط للحقن تحت الجلد. تحدث إلى طبيبك إذا كنت بحاجة إلى حقن الإنسولين بطريقة أخرى.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">قد تؤثر بعض الظروف والأنشطة على حاجتك للإنسولين. استشِر الطبيب:</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة<strong> </strong>في الكليتين أو الكبد أو الغدد الكظرية أو الغدة النخامية أو الغدة الدرقية.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تمارس تمارين رياضية<strong> </strong>أكثر من المعتاد أو إذا كنت ترغب في تغيير النظام الغذائي الخاص بك، حيث قد يؤثر ذلك على مستوى السكر في الدم.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضاً، استمر في استعمال الإنسولين واستشر طبيبك المعالج.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مسافراً خارج البلاد،<strong> </strong>قد يؤثر السفر إلى المناطق البعيدة على مقدار احتياجك من الإنسولين وتوقيت الجرعة.</p><p dir="RTL"><strong>تغييرات جلدية في موضع الحقن</strong></p><p dir="RTL">يجب تغيير مكان الحقن في كل مرة لمنع حدوث تغيرات في الأنسجة الدهنية تحت الجلد، مثل زيادة سماكة الجلد أو تقلصه أو تكوَّن كتل تحت الجلد. قد لا يعمل الإنسولين بشكل جيد إذا تم حقنه في مناطق ذات كتل أو مناطق سميكة أو متقلصة (انظر القسم 3 كيفية استعمال نوفومِكس&trade;). اخبر طبيبك عند ملاحظة أي تغييرات في موضع الحقن. اخبر طبيبك إذا كنت تقوم في الوقت الحالي بالحقن في هذه المناطق قبل البدء بالحقن في مناطق أخرى. قد يخبرك طبيبك أن تقوم بفحص سكر دمك بشكل متكرر وأن تعدل جرعتك من الإنسولين أو جرعة الأدوية الفموية الأخرى المخفضة لسكر الدم.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستعمل نوفومِكس<sup>&trade;</sup> 30 لعلاج مرض السكري لدى المراهقين والأطفال ممن تتراوح أعمارهم بين 10 سنوات وأكثر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك خبرة محدودة في استعمال نوفومِكس<sup>&trade;</sup> 30 لعلاج الأطفال ما بين 6 و9 سنوات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولا تتوفر أية بيانات بخصوص استعمال نوفومِكس<sup>&trade;</sup> 30 مع الأطفال الأصغر من 6 سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ونوفومِكس<sup>&trade;</sup></strong><strong> 30</strong></p><p dir="RTL"><strong>يُرجى إخبار الطبيب أو الممرضة أو الصيدلي</strong> إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى في المستقبل. تؤثر بعض الأدوية في مستوى السكر في الدم، وقد يعني هذا ضرورة تغيير جرعة الإنسولين. فيما يلي الأدوية الأكثر شيوعاً التي قد تؤثر في علاجك بالإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد ينخفض مستوى السكر في الدم </strong>(هبوط سكر الدم) إذا أخذت:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لعلاج مرض السكري</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أوكسيديز أحادي الأمين (MAOI) (تُستخدم لعلاج الاكتئاب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا (تستخدم لعلاج ارتفاع ضغط الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثَبِّطَات الإِنْزيم المُحَوِّل للأنجيوتنسين (ACE) - (تستخدم لعلاج بعض مشاكل القلب أو ضغط الدم المرتفع)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الساليسيلات (تُستخدم لتخفيف الألم و خفض الحمى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السترويدات البنائية - مثل التيستوستيرون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السالفوناميدات (يُستخدم لعلاج العدوى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يرتفع مستوى السكر في الدم</strong> (ارتفاع سكر الدم) إذا أخذت:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل عن طريق الفم (حبوب منع الحمل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثيازيدات (يُستخدم لعلاج ارتفاع ضغط الدم أو الاحتفاظ المفرط بالسوائل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية القشرانية السكرية (مثل &quot;الكورتيزون&quot; المستخدم لعلاج الالتهابات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الدرقية (تُستخدم لعلاج اضطرابات الغدة الدرقية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحاكيات الودية (مثل الإبينيفرين [الأدرينالين]، أو السالبوتامول، أو التيربوتالين المستخدم لعلاج الربو)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون النمو (دواء لتحفيز الهيكل العظمي والنمو الجسدي وله تأثير واضح على عمليات التمثيل الغذائي في الجسم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانازول (دواء يؤثر على التبويض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي <strong>أوكتوريوتيد ولانريوتيد</strong> (يستخدمان لعلاج ضخامة الأطراف، وهو اضطراب هرموني نادر يحدث عادة عند البالغين في منتصف العمر، وينتج عن إنتاج زائد لهرمون النمو من الغدة النخامية ) إلى زيادة أو نقصان مستوى السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تضعف <strong>حاصرات بيتا</strong> (تُستخدم لعلاج ارتفاع ضغط الدم) أو تكبح تماماً أعراض التحذير الأولى التي تساعدك على التعرّف على نقص مستوى السكر في الدم.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>ثيازوليدينديون</strong> (فئة من الأدوية المضادة للسكري يتم تناولها عن طريق الفم وتُستخدم لعلاج داء السكري من النوع الثاني)</p><p dir="RTL">بعض المرضى المصابين بالنوع الثاني من داء السكري وأمراض القلب لفترات طويلة أو المصابين بسكتة دماغية سابقاً، والذين عولجوا بأدوية ثيازوليدينديون مع الإنسولين، تعرّضوا إلى الإصابة بفشل القلب. فاحرص على إبلاغ الطبيب المعالج في أقرب وقت ممكن إذا كنت تعاني من علامات فشل القلب مثل ضيق التنفس غير العادي أو زيادة الوزن السريعة أو التورم الموضعي (وذمة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد أخذت أي من الأدوية الواردة هنا، أخبر الطبيب أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شرب الكحول واستعمال نوفومِكس<sup>&trade;</sup></strong><strong> 30</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الكحول، فقد تتغير حاجتك للإنسولين لأن مستوى السكر في الدم قد يرتفع أو ينخفض. ولذلك يوصى بالمراقبة الدقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً، أو تعتقدين أنكِ حامل أو تنوين الحمل، فاستشيري طبيبك قبل أخذ هذا الدواء. توجد خبرة سريرية محدودة مع استعمال &rlm;‫إنسولين أسبارت أثناء الحمل. قد يلزم تغيير جرعة الإنسولين أثناء الحمل وبعد الولادة. ويعد التحكم الدقيق بمرض السكري، وخاصة الوقاية من نقص سكر الدم، أمراً هاماً لصحة طفلك.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا توجد قيود على العلاج باستعمال نوفومِكس<sup>&trade;</sup> 30 أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استشيري الطبيب أو الممرضة أو الصيدلي</strong> قبل تناول أي دواء أثناء الحمل أو الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يرجى سؤال الطبيب عما إذا كان بإمكانك قيادة سيارة أو تشغيل آلة في الحالات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص سكر الدم بشكل متكرر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجدت صعوبة في التعرف على نقص سكر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان مستوى السكر في الدم منخفضاً أو مرتفعاً، فقد يؤثر ذلك على تركيزك وقدرتك على التصرف، وبالتالي قدرتك على القيادة أو تشغيل الآلات. فيرجى الانتباه إلى أنك قد تعرض نفسك أو الآخرين للخطر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة عن بعض مكونات دواء نوفومِكس<sup>&trade;</sup></strong><strong> 30</strong></p><p dir="RTL">يحتوي نوفومِكس<sup>&trade;</sup> 30 على أقل من 1 ميليمول من الصوديوم (23 ملجم) لكل جرعة، &rlm;‫وهذا يعني أن نوفومِكس<sup>&trade;</sup> 30 &quot;خالٍ من الصوديوم&quot; تقريباً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة الإنسولين وموعدها</strong></p><p dir="RTL">يجب دوماً استخدام الإنسولين وضبط جرعتك كما أخبرك الطبيب تماماً. ويجب استشارة الطبيب أو الممرضة أو الصيدلي في حالة الشك بشأن طريقة استخدامه على الوجه الصحيح.</p><p dir="RTL">يتم استعمال نوفومِكس<sup>&trade;</sup> 30 عموماً قبل تناول الطعام مباشرة . واحرص على تناول وجبة خفيفة أو وجبة في غضون 10 دقائق من الحقن لتجنب نقص السكر في الدم. وعند الضرورة، يمكن استعمال نوفومِكس<sup>&trade;</sup> 30 بعد تناول الطعام بوقت قصير.</p><p dir="RTL">انظر <em>كيفية ومكان الحقن</em> أدناه لمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تغير نوع الإنسولين، إلا إذا أخبرك طبيبك بذلك. وإذا نصحك الطبیب المعالج بتغيير نوع الإنسولین إلی آخر، قد یتعین علیك ضبط الجرعة مع طبیبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند استخدام نوفومِكس<sup>&trade;</sup> 30 مع الأدوية المضادة للسكري المتناولة عن طريق الفم و/أو مع المنتجات المضادة للسكري عن طريق الحقن، قد یتعین علیك ضبط الجرعة مع طبیبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>الاستعمال مع</strong><strong> الأطفال والمراهقين</strong></p><p dir="RTL">يمكن استخدام نوفومِكس<sup>&trade;</sup> 30 للمراهقين والأطفال بدءاً من عمر 10 سنوات، عندما يُفضل استخدام الإنسولين الممزوج مسبقاً. توجد خبرة محدودة بخصوص الأطفال الذين يبلغ عمرهم من 6 حتى 9 سنوات. ولا تتوفر أية بيانات بخصوص استعمال نوفومِكس<sup>&trade;</sup> 30 مع الأطفال الأصغر من 6 سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال مع فئات خاصة من المرضى</strong></p><p dir="RTL">إذا كنت تعاني من انخفاض وظائف الكلى أو الكبد أو كان عُمرك يزيد على 65 سنة، يجب عليك التحقق من نسبة السكر في الدم بشكل أكثر انتظاماً ومناقشة تغيرات جرعة الإنسولين مع طبيبك المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية ومكان الحقن</strong></p><p dir="RTL">يستعمل نوفومِكس<sup>&trade;</sup> 30 عن طريق <strong>الحقن تحت الجلد</strong>. ويحظر حقن الإنسولين مباشرة في الوريد أو في العضل. نوفومِكس<sup>&trade;</sup> 30 فلكس بن<sup>&trade;</sup> مناسب فقط للحقن تحت الجلد. تحدث إلى طبيبك إذا كنت بحاجة إلى حقن الإنسولين بطريقة أخرى.</p><p dir="RTL">مع كل حقنة يجب تغيير موضع الحقن في منطقة معينة من الجلد. فقد يقلل هذا من خطر تكون الكتل أو تورم الجلد (انظر<em> </em>القسم 4، <em>الآثار الجانبية المحتملة</em>). أفضل أماكن للحقن هي الجزء الأمامي من الخصر (البطن) ,الأرداف ومقدمة الفخذ والجزء العلوي من الذراعين. وسيعمل الإنسولين بسرعة أكبر إذا قمت بحقنه في الخصر (البطن). ولا تنسى قياس مستوى السكر في الدم بانتظام دائماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استعمال نوفومِكس<sup>&trade;</sup></strong><strong> 30</strong><strong> فلكس بن<sup>&trade;</sup></strong></p><p dir="RTL">نوفومِكس<sup>&trade;</sup> 30 فلكس بن<sup>&trade;</sup> هو قلم معبأ مسبقاً مُرمَّز بالألوان ومخصص للاستعمال لمرة واحدة فقط ويحتوي على مزيج من الإنسولين سريع المفعول ومتوسط المفعول بنسبة 30/70.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اقرأ بعناية التعليمات الخاصة بالاستعمال والواردة بنشرة العبوة هذه. حيث يجب استخدام القلم كما هو موضح في تعليمات الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأكد دائماً من استخدام القلم الصحيح قبل حقن الإنسولين.</p><p dir="RTL"><strong>في حالة استعمال كمية إنسولين أكبر مما ينبغي</strong></p><p dir="RTL">في حال استعمال جرعه زائده من الإنسولين، ستنخفض نسبة السكر في الدم جداً (هبوط سكر الدم). انظر أ) <em>&rlm;</em>‫<em>ملخص الآثار الجانبية الخطيرة والشائعة جداً</em> في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان استعمال الإنسولين</strong></p><p dir="RTL">إذا نسيت أخذ جرعة الإنسولين، فقد يرتفع مستوى السكر في الدم أكثر من اللازم (زيادة سكر الدم). انظر ج) <em>آثار ناشئة عن داء السكري</em> في الجزء 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استعمال الإنسولين</strong></p><p dir="RTL">لا تتوقف عن استعمال الإنسولين دون التحدث إلى الطبيب الذي سيخبرك بما يجب القيام به. قد يؤدي ذلك إلى ارتفاع حاد في مستوى السكر في الدم (ارتفاع شديد في نسبة السكر في الدم) والحماض الكيتوني. انظر ج) <em>آثار ناشئة عن داء السكري</em> في الجزء 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، ينبغي استشارة الطبيب أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ)&nbsp;&nbsp; &rlm;</strong>‫<strong>ملخص الآثار الجانبية الخطيرة والشائعة جداً </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من الآثار الجانبية الشائعة جداً <strong><em>انخفاض مستوى السكر في الدم (نقص مستوى السكر في الدم)</em></strong>. حيث يمكن أن يصيب أكثر من شخص من كل 10 أشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث انخفاض السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم حقن جرعة زائدة من الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولت كمية من الطعام أقل من اللازم أو لم تتناول إحدى الوجبات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمرنت أكثر من المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫شربت الكحول (انظر <em>شرب الكحول واستعمال نوفومِكس<sup>&trade;</sup></em><em> 30</em>&rlm; في القسم 2).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات نقص السكر في الدم:</strong> التعرق البارد؛ شحوب الجلد وبرودته؛ صداع؛ سرعة ضربات القلب؛ الشعور &nbsp;&nbsp;بالغثيان او القئ؛ الشعور بالجوع المفرط؛ تغييرات مؤقتة في الرؤية؛ الشعور بالنعاس؛ الشعور بالتعب والضعف بشكل غير عادي؛ التوتر أو الرعشة؛ الشعور بالقلق؛ الشعور بالارتباك؛ صعوبة التركيز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي الانخفاض الحاد في مستوى السكر في الدم إلى فقدان الوعي. وإذا لم يتم علاج الانخفاض الحاد في مستوى السكر في الدم لفترة طويلة، قد يتسبب ذلك في تلف الدماغ (مؤقت أو دائم) أو حتى الوفاة. قد تتعافى بسرعة أكبر من حالة فقدان الوعي عن طريق إعطائك حقنة هرمون الجلوكاجون بواسطة شخص يعرف كيفية استخدامها. وإذا كنت تستعمل الجلوكاجون، ستحتاج إلى تناول الجلوكوز أو وجبة خفيفة سكرية بمجرد الرجوع إلى وعيك. وإذا لم تستجيب لحقن الجلوكاجون، يجب أن تذهب للمستشفى للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله في حالة انخفاض مستوى السكر في الدم:</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة انخفاض مستوى السكر في الدم، يجب عليك تناول أقراص الجلوكوز أو غيرها من الوجبات الخفيفة عالية السكر (الحلويات أو البسكويت أو عصير الفاكهة). ينبغي قياس مستوى السكر في الدم وأخذ قسط من الراحة. ولذلك ينبغي دائماً الاحتفاظ بأقراص الجلوكوز أو الوجبات الخفيفة عالية السكر معك من باب الاحتياط.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تختفي أعراض انخفاض مستوى السكر في الدم أو عند استقرار مستوى السكر في الدم، واصل العلاج المعتاد بالإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مستوى السكر في الدم لدرجة فقدان الوعي، أو إذا احتجت إلى حقن الجلوكاجون أو إذا كنت قد تعرضت للعديد من حالات انخفاض مستوى السكر في الدم، عليك استشارة طبيبك. حيث قد يلزم تعديل كمية الإنسولين أو توقيت تعاطيه أو كمية الطعام المتناول أو التمارين الرياضية الممارسة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الأشخاص ذوي الصلة أنك مصاب بمرض السکري وأطلعهم على العواقب التي قد تحدث لك، بما في ذلك خطر فقدان الوعي بسبب نقص مستوى السكر في الدم. أخبرهم أنه في حال فقدانك للوعي، يجب عليهم إسنادك إلى جانبك والحصول على المساعدة الطبية على الفور. ولا يجب أن يعطوك أي طعام أو شراب، لأنه قد ينحشر في حلقك ويصيبك بالاختناق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>تفاعلات الحساسية الخطيرة</em></strong> لدواء نوفومِكس<sup>&trade;</sup> 30 أو أحد مكوناته (يسمى التفاعل التحسسي العام) هو من الأعراض الجانبية النادرة جداً، ولكن قد يكون مهدداً للحياة. حيث يمكن أن يصيب أقل من شخص من كل 10000 شخص.</p><p dir="RTL">&nbsp;</p><p>اطلب المشورة الطبية فوراً:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انتشرت علامات الحساسية إلى أجزاء أخرى من جسمك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت فجأة بأنك ليست على ما يرام و: بدأت في التعرق أو الشعور بالغثيان أو القيء أو وجدت صعوبة التنفس أو شعرت بسرعة ضربات القلب أو بالدوار.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت وجود أي من هذه العلامات، فاطلب المشورة الطبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تغييرات جلدية في موضع الحقن: </strong>إذا كنت تقوم بحقن الإنسولين كل مرة في نفس المكان، قد تتقلص الأنسجة الدهنية تحت الجلد في موضع الحقن (الحثل الشحمي)&nbsp; أو تتضخم (التكتل الشحمي) (قد تؤثر في أقل من شخص واحد في كل 100 شخص). قد تتكوَّن الكتل تحت الجلد بسبب تراكم البروتين بما يسمى الداء النشواني ( النشواني الجلدي, معدل التكرار غير معروف). قد لا يعمل الإنسولين بشكل جيد إذا تم حقنه في مناطق ذات كتل أو مناطق سميكة أو متقلصة. قم بتغيير مكان الحقن في كل مرة لمنع حدوث مثل هذه التغييرات .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قائمة بآثار جانبية أخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية غير الشائعة</em></strong></p><p dir="RTL">يمكن أن تصيب أقل من شخص من كل 100 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات حدوث الحساسية:</strong> تفاعلات الحساسية الموضعية (شعور بألم، احمرار، شَرَى، التهاب، كدمات، تورم، حكة) في موضع الحقن. وعادةً ما تختفي هذه التفاعلات بعد بضعة أسابيع من استعمال الإنسولين. أما إذا لم تختفِ، يُرجى استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;</strong>‫<strong>مشاكل الرؤية:</strong> عندما تبدأ أول جرعة علاج بالإنسولين، قد تصاب بمشاكل في الرؤية، ولكن عادة ما يكون ذلك الاضطراب مؤقتاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;</strong>‫<strong>تورم المفاصل:</strong> عند بدء استعمال الإنسولين، قد يسبب احتباس الماء حدوث تورم حول الكاحلين والمفاصل الأخرى. وعادةً ما تختفي هذه الأعراض سريعاً. ولكن إذا لم تختفي الأعراض، ينبغي استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اعتلال الشبكية السكري</strong> &rlm;‫(مرض بالعين مرتبط بمرض السكري والذي يمكن أن يؤدي إلى فقدان الرؤية):<strong> </strong>‫إذا كنت تعاني من اعتلال الشبكية السكري مع تطور مستوى السكر في الدم بسرعة كبيرة، قد يزداد اعتلال الشبكية سوءاً. ولذلك يجب استشارة الطبيب المعالج في هذا الشأن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الأعراض الجانبية النادرة </em></strong></p><p dir="RTL">يمكن أن تصيب أقل من شخص من كل 1000 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;</strong>‫<strong>الاعتلال العصبي المؤلم</strong> (ألم ناتج عن تلف الأعصاب) إذا تحسّن مستوى السكر في الدم بشكل سريع جداً، فقد تشعر بألم مرتبط بالأعصاب. وهذا ما يسمى بالاعتلال العصبي المؤلم الحاد، وعادة ما يكون عابراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">في حالة إصابتك بأي آثار جانبية، استشر الطبيب أو الصيدلي أو الممرضة. يشمل هذا أية آثار جانبية محتملة غير واردة في هذه النشرة. فبالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;</strong>‫<strong>آثار ناشئة عن داء السكري</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>ارتفاع السكر في الدم </em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث ارتفاع السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم تحقن جرعة كافية من الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نسيت جرعة الإنسولين أو توقفت عن تناول الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استعملت كمية إنسولين أقل مما تحتاج إليه بشكل متكرر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أُصبت بالعدوى و/أو الحمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكلت كمية أكبر من المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمرنت أقل من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;</strong>‫<strong>العلامات التحذيرية لارتفاع مستوى السكر في الدم:</strong></p><p dir="RTL">تظهر العلامات التحذيرية تدريجياً. وتشمل: زيادة التبول؛ الشعور بالعطش؛ فقدان الشهية؛ الشعور بالغثيان أو القيء؛ الشعور بالنعاس أو التعب، الشعور بالحرارة، جفاف الجلد؛ جفاف الفم ورائحة فاكهة (أسيتون) في النفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله في حالة حدوث ارتفاع شديد في مستوى السكر في الدم لديك:</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فإذا كنت تعاني من أي من العلامات الواردة أعلاه، اختبر مستوى السكر في الدم لديك، واختبر البول لمعرفة الكيتونات في حالة الاستطاعة، ثم اطلب المشورة الطبية على الفور.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشير هذه العلامات إلى حالة خطيرة جداً تسمى الحماض الكيتوني السكري (تراكم الحمض في الدم لأن الجسم يكسر الدهون بدلاً من السكر). وإذا لم تعالج هذه الحالة، قد تؤدي إلى الدخول في غيبوبة سكر والوفاة في أخر الأمر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عند متناول ومرأى الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على ملصق قلم الحقن فلكس بن<sup>&trade;</sup> والعبوة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">احرص دائماً على وضع غطاء القلم على قلم فلكس بن<sup>&trade;</sup> في حال عدم استخدامه من أجل حمايته من الضوء. يجب حماية نوفومِكس<sup>&trade;</sup> 30 من الحرارة والضوء المفرط.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قبل الفتح: </strong>يجب تخزين نوفومِكس<sup>&trade;</sup> 30 فلكس بن<sup>&trade;</sup> غير المستعمل في الثلاجة في درجة حرارة 2 إلى 8 درجات مئوية، بعيداً عن عنصر التبريد. يُراعى عدم التجميد.</p><p dir="RTL">قبل استخدام نوفومِكس<sup>&trade;</sup> 30 فلكس بن<sup>&trade;</sup>، أخرجه من الثلاجة. يوصى بإعادة تعليق الإنسولين حسب التعليمات في كل مرة يتم فيها استخدام قلم جديد. انظر تعليمات الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء الاستخدام أو عند الاحتفاظ بالدواء كعبوة بديلة:</strong> يجب عدم تخزين نوفومِكس<sup>&trade;</sup> 30 فلكس بن<sup>&trade;</sup> المستعمل أو الذي يتم استعماله كعبوة بديلة في الثلاجة. بل يمكنك حملها معك وحفظها في درجة حرارة الغرفة (أقل من 30 درجة مئوية) لمدة تصل إلى 4 أسابيع.</p><p dir="RTL">&nbsp;</p><p>لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات نوفومِكس<sup>&trade;</sup></strong><strong> 30</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إنسولين أسبارت. نوفومِكس<sup>&trade;</sup> 30 عبارة عن مزيج يتكون من 30% من إنسولين أسبارت القابل للذوبان و70% إنسولين أسبارت مبلور مع البروتامين. يحتوي كل 1 مل على 100 وحدة إنسولين أسبارت. يحتوي كل قلم معبأ مسبقاً على 300 وحدة إنسولين أسبارت لكل 3 مل معلق للحقن.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي جلسرين وفينول وميتاكرسول وكلوريد الزنك وثنائي هيدرات فوسفات ثنائي الصوديوم وكلوريد الصوديوم وبروتامين الكبريتات وحمض الهيدروكلوريك وهيدروكسيد الصوديوم وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر نوفومِكس<sup>&trade;</sup> 30 في صورة معلق للحقن في قلم معبأ مسبقاً. تحتوي الخرطوشة على كرة زجاجية لتسهيل إعادة التعليق. بعد إعادة التعليق، من المُفترض أن يظهر السائل بلون أبيض متجانس غائم ومائي.</p><p dir="RTL">لا تستخدم الإنسولين إذا كان لا يبدو بلون أبيض متجانس غائم ومائي بعد إعادة التعليق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر عبوات بها 5 أو 10 أقلام للحقن معبأة مسبقاً بحجم 3 مل. لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المعلق غائم وأبيض ومائي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس -2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NovoMix 30 FlexPen 100 units/ml suspension for injection in pre-filled pen
	
	

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NovoMix 30 FlexPen
1 ml of the suspension contains 100 units soluble insulin aspart*/protamine-crystallised insulin aspart* in the ratio 30/70 (equivalent to 3.5 mg). 1 pre-filled pen contains 3 ml equivalent to 300 units.
	
*Insulin aspart is produced in Saccharomyces cerevisiae by recombinant DNA technology.
	
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection.
	
The suspension is cloudy, white and aqueous.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NovoMix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10&nbsp;years and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>&nbsp;</p><p>The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.</p><p>&nbsp;</p><p>NovoMix 30 dosing is individual and determined in accordance with the needs of the patient. Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.</p><p><em>&nbsp;</em></p><p>In patients with type 2 diabetes, NovoMix 30 can be given as monotherapy. NovoMix 30 can also be given in combination with oral antidiabetic medicinal products and/or GLP-1 receptor agonists. For patients with type 2 diabetes, the recommended starting dose of NovoMix 30 is 6&nbsp;units at breakfast and 6&nbsp;units at dinner (evening meal). NovoMix 30 can also be initiated once daily with 12&nbsp;units at dinner (evening meal). When using NovoMix 30 once daily, it is generally recommended to move to twice daily when reaching 30&nbsp;units by splitting the dose into equal breakfast and dinner doses. If twice daily dosing with NovoMix 30 results in recurrent daytime hypoglycaemic episodes, the morning dose can be split into morning and lunchtime doses (thrice daily dosing).</p><p>&nbsp;</p><p>The following titration guideline is recommended for dose adjustments:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Pre-meal blood glucose level</p></td><td style="vertical-align:top"><p>NovoMix 30 dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>&lt;4.4&nbsp;mmol/l</p></td><td style="vertical-align:top"><p>&lt;80&nbsp;mg/dl</p></td><td style="vertical-align:top"><p>-2&nbsp;units</p></td></tr><tr><td style="vertical-align:top"><p>4.4&ndash;6.1&nbsp;mmol/l</p></td><td style="vertical-align:top"><p>80&ndash;110&nbsp;mg/dl</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>6.2&ndash;7.8&nbsp;mmol/l</p></td><td style="vertical-align:top"><p>111&ndash;140&nbsp;mg/dl</p></td><td style="vertical-align:top"><p>+2&nbsp;units</p></td></tr><tr><td style="vertical-align:top"><p>7.9&ndash;10&nbsp;mmol/l</p></td><td style="vertical-align:top"><p>141&ndash;180&nbsp;mg/dl</p></td><td style="vertical-align:top"><p>+4&nbsp;units</p></td></tr><tr><td style="vertical-align:top"><p>&gt;10&nbsp;mmol/l</p></td><td style="vertical-align:top"><p>&gt;180&nbsp;mg/dl</p></td><td style="vertical-align:top"><p>+6&nbsp;units</p></td></tr></tbody></table><p>The lowest of the three previous days&rsquo; pre-meal blood glucose levels should be used. The dose should not be increased if hypoglycaemia occurred within these days. Dose adjustments can be made once a week until target HbA<sub>1c</sub> is reached. Pre-meal blood glucose levels should be used to evaluate the adequacy of the preceding dose.</p><p>&nbsp;</p><p>In patients with type 2 diabetes, a dose reduction of 20% is recommended for patients with an HbA<sub>1c</sub> less than 8% when a GLP-1 receptor agonist is added to NovoMix 30, to minimise the risk of hypoglycaemia. For patients with an HbA<sub>1c</sub> higher than 8% a dose reduction should be considered. Subsequently, dosage should be adjusted individually.</p><p>&nbsp;</p><p>In patients with type 1 diabetes, the individual insulin requirement is usually between 0.5 and 1.0&nbsp;unit/kg/day. NovoMix 30 may fully or partially meet this requirement.</p><p>&nbsp;</p><p>Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.</p><p><strong>Special populations</strong></p><p>&nbsp;</p><p><em>Elderly (&ge;65&nbsp;years old)</em></p><p>NovoMix&nbsp;30 can be used in elderly patients; however there is limited experience with the use of NovoMix&nbsp;30 in combination with oral antidiabetic medicinal products in patients older than 75&nbsp;years.</p><p>In elderly patients, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.</p><p><u>&nbsp;</u></p><p><em>Renal and hepatic impairment</em></p><p>Renal or hepatic impairment may reduce the patient&rsquo;s insulin requirements.</p><p>In patients with renal or hepatic impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>NovoMix&nbsp;30 can be used in adolescents and children aged 10&nbsp;years and above when premixed insulin is preferred. There is limited clinical experience with NovoMix 30 in children aged 6&ndash;9&nbsp;years (see section 5.1).</p><p>No data are available for NovoMix 30 in children below 6&nbsp;years of age.</p><p>&nbsp;</p><p><strong>Transfer from other insulin medicinal products</strong></p><p>&nbsp;</p><p>When transferring a patient from biphasic human insulin to NovoMix&nbsp;30, start with the same dose and regimen. Then titrate according to individual needs (see the titration guideline in the table above).</p><p>Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>&nbsp;</p><p>NovoMix 30 is a biphasic suspension of the insulin analogue, insulin aspart. The suspension contains rapid-acting and intermediate-acting insulin aspart in the ratio 30/70.</p><p>&nbsp;</p><p>NovoMix 30 is for subcutaneous administration <strong>only</strong>.</p><p>NovoMix 30 is administered subcutaneously by injection in the thigh or in the abdominal wall. If convenient, the gluteal or deltoid region may be used. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8). The influence of different injection sites on the absorption of NovoMix 30 has not been investigated. The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.</p><p>&nbsp;</p><p>NovoMix 30 has a faster onset of action than biphasic human insulin and should generally be given immediately before a meal. When necessary, NovoMix 30 can be given soon after a meal.</p><p>&nbsp;</p><p>For detailed user instructions, please refer to the package leaflet.</p><p>&nbsp;</p><p><u>NovoMix 30 Penfill</u></p><p><em>Administration with an insulin delivery system</em></p><p>NovoMix 30 Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles. NovoMix 30 Penfill is only suitable for subcutaneous injections from a reusable pen. If administration by syringe is necessary, a vial should be used.</p><p>&nbsp;</p><p><u>NovoMix 30 FlexPen</u></p><p><em>Administration with FlexPen</em></p><p>NovoMix 30 FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist needles. FlexPen delivers 1&ndash;60&nbsp;units in increments of 1&nbsp;unit. NovoMix 30 FlexPen is only suitable for subcutaneous injections. If administration by syringe is necessary, a vial should be used.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NovoMix 30 must not be administered intravenously, as it may result in severe hypoglycaemia. Intramuscular administration should be avoided. NovoMix 30 is not to be used in insulin infusion pumps.</p><p>&nbsp;</p><p>Before travelling between different time zones, the patient should seek the doctor&rsquo;s advice since this may mean that the patient has to take the insulin and meals at different times.</p><p>&nbsp;</p><p><strong>Hyperglycaemia</strong></p><p>&nbsp;</p><p>Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Usually, the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath. In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.</p><p>&nbsp;</p><p><strong>Hypoglycaemia</strong></p><p>&nbsp;</p><p>Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia.</p><p>&nbsp;</p><p>Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. In case of hypoglycaemia or if hypoglycaemia is suspected, NovoMix must not be injected. After stabilisation of the patient&rsquo;s blood glucose, adjustment of the dose should be considered (see sections 4.2, 4.8 and 4.9).</p><p>&nbsp;</p><p>Compared with biphasic human insulin, NovoMix 30 may have a more pronounced glucose lowering effect up to 6&nbsp;hours after injection. This may have to be compensated for in the individual patient</p><p>through adjustment of insulin dose and/or food intake.</p><p>&nbsp;</p><p>Patients whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly. Usual warning symptoms may disappear in patients with longstanding diabetes.</p><p>&nbsp;</p><p>Tighter control of glucose levels can increase the potential for hypoglycaemic episodes and therefore require special attention during dose intensification as outlined in section 4.2.</p><p>&nbsp;</p><p>Since NovoMix 30 should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption of food might be expected.</p><p>&nbsp;</p><p>Concomitant illness, especially infections and feverish conditions, usually increases the patient&rsquo;s insulin requirements. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose.</p><p>&nbsp;</p><p>When patients are transferred between different types of insulin medicinal products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.</p><p>&nbsp;</p><p><strong>Transfer from other insulin medicinal products </strong></p><p>&nbsp;</p><p>Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal insulin, human insulin or insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dose. Patients transferred to NovoMix&nbsp;30 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. If an adjustment is needed, it may occur with the first dose or during the first few weeks or months.</p><p>&nbsp;</p><p><strong>Injection site reactions</strong><strong> </strong></p><p>&nbsp;</p><p>As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area reduces the risk of developing these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of NovoMix 30.</p><p>&nbsp;</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p><u>&nbsp;</u></p><p>Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medications may be considered.</p><p>&nbsp;</p><p><strong>Combination of NovoMix with pioglitazone</strong></p><p>&nbsp;</p><p>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and NovoMix is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</p><p>&nbsp;</p><p><strong>Avoidance of accidental mix-ups/medication errors</strong></p><p>&nbsp;</p><p>Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between NovoMix and other insulin products.</p><p>&nbsp;</p><p><strong>Insulin antibodies</strong></p><p>&nbsp;</p><p>Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.</p><p>&nbsp;</p><p><strong>Traceability</strong></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of medicinal products are known to interact with the glucose metabolism.</p><p>&nbsp;</p><p>The following substances may reduce the patient&rsquo;s insulin requirements:</p><p>Oral antidiabetic medicinal products, GLP-1 receptor agonists, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulfonamides.</p><p>&nbsp;</p><p>The following substances may increase the patient&rsquo;s insulin requirements:</p><p>Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.</p><p>&nbsp;</p><p>Beta-blockers may mask the symptoms of hypoglycaemia.</p><p>&nbsp;</p><p>Octreotide/lanreotide may either increase or decrease the insulin requirement.</p><p>&nbsp;</p><p>Alcohol may intensify or reduce the hypoglycaemic effect of insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy </strong></p><p>&nbsp;</p><p>There is limited clinical experience with NovoMix 30 in pregnancy.</p><p>&nbsp;</p><p>Animal reproduction studies have not revealed any differences between insulin aspart and human insulin regarding embryotoxicity or teratogenicity.</p><p>&nbsp;</p><p>In general, intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimesters. After delivery, insulin requirements return rapidly to pre-pregnancy levels.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>&nbsp;</p><p>There are no restrictions on treatment with NovoMix 30 during breast-feeding. Insulin treatment of the nursing mother presents no risk to the baby. However, the NovoMix 30 dose may need to be adjusted.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p><u>&nbsp;</u></p><p>Animal reproduction studies have not revealed any differences between insulin aspart and human insulin regarding fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p><p>&nbsp;</p><p>Patients should be advised to take precautions to avoid hypoglycaemia while driving or operating a machine. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving or operating a machine should be considered in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong>Summary of the safety profile</strong></p><p>&nbsp;</p><p>Adverse reactions observed in patients using NovoMix are mainly due to the pharmacological effect of insulin aspart.</p><p>&nbsp;</p><p>The most frequently reported adverse reaction during treatment is hypoglycaemia. The frequencies of hypoglycaemia vary with patient population, dose regimens and level of glycaemic control, please see Description of selected adverse reactions below.</p><p>&nbsp;</p><p>At the beginning of the insulin treatment, refraction anomalies, oedema and injection site reactions (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site) may occur. These reactions are usually of a transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.</p><p>&nbsp;</p><p><strong>Tabulated list of adverse reactions</strong></p><p>&nbsp;</p><p>The adverse reactions listed below are based on clinical trial data and classified according to MedDRA frequency and System Organ Class. Frequency categories are defined according to the following convention: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon &ndash; Urticaria, rash, eruptions</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare &ndash; Anaphylactic reactions*</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common &ndash; Hypoglycaemia*</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Rare &ndash; Peripheral neuropathy (painful neuropathy)</p><p><strong>&nbsp;</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p><p><u>&nbsp;</u></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Uncommon &ndash; Refraction disorders</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon &ndash; Diabetic retinopathy</p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon &ndash; Lipodystrophy*</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known &ndash; Cutaneous amyloidosis*&dagger;</p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Uncommon &ndash; Oedema</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon &ndash; Injection site reactions</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* see Description of selected adverse reactions</p><p>&dagger; ADR from postmarketing sources.</p><p>&nbsp;</p><p><strong>Description of selected adverse reactions</strong></p><p>&nbsp;</p><p><em>Anaphylactic reactions: </em></p><p>The occurrence of generalised hypersensitivity reactions (including generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure) is very rare but can potentially be life-threatening.</p><p>&nbsp;</p><p><em>Hypoglycaemia:</em></p><p>The most frequently reported adverse reaction is hypoglycaemia. It may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentrating, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.</p><p>&nbsp;</p><p>In clinical trials, the frequency of hypoglycaemia varied with patient population, dose regimens and level of glycaemic control. During clinical trials, the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders:</em></p><p>Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>&nbsp;</p><p>Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general population.</p><p>&nbsp;</p><p><strong>Other special populations</strong></p><p>&nbsp;</p><p>Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>Please report adverse drug events to:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient&rsquo;s requirement are administered:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient always carries sugar-containing products.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1&nbsp;mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15&nbsp;minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting. ATC code: A10AD05.</p><p>&nbsp;</p><p>NovoMix 30 is a biphasic suspension of 30% soluble insulin aspart (rapid-acting human insulin analogue) and 70% protamine-crystallised insulin aspart (intermediate-acting human insulin analogue).</p><p>&nbsp;</p><p><strong>Mechanism of action and pharmacodynamic effects</strong></p><p>&nbsp;</p><p>The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.</p><p>&nbsp;</p><p>NovoMix 30 is a biphasic insulin, which contains 30% soluble insulin aspart. This has a rapid onset of action, thus allowing it to be given closer to a meal (within zero to 10&nbsp;minutes of the meal) when compared to soluble human insulin. The crystalline phase (70%) consists of protamine-crystallised insulin aspart, which has an activity profile similar to that of human NPH insulin.</p><p>&nbsp;</p><p>When NovoMix 30 is injected subcutaneously, the onset of action will occur within 10 to 20&nbsp;minutes of injection. The maximum effect is exerted between 1 and 4&nbsp;hours after injection. The duration of action is up to 24&nbsp;hours (Figure 1).</p><p><img src="data:image/png;base64,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" alt="" width="762" height="392" vspace="0" hspace="0" border="0" style="width:762px;height:392px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Clinical efficacy and safety</strong></p><p>&nbsp;</p><p>In a 3&nbsp;month trial in patients with type 1 and type 2 diabetes, NovoMix 30 showed equal control of glycosylated haemoglobin compared to treatment with biphasic human insulin 30. Insulin aspart is equipotent to human insulin on a molar basis. Compared to biphasic human insulin 30, administration of NovoMix 30 before breakfast and dinner resulted in lower postprandial blood glucose after both meals (breakfast and dinner).</p><p>&nbsp;</p><p>A meta-analysis including nine trials in patients with type 1 and type 2 diabetes showed that fasting blood glucose was higher in patients treated with NovoMix 30, than in<strong><em> </em></strong>patients treated with biphasic human insulin 30.</p><p>&nbsp;</p><p>In one study, 341&nbsp;patients with type 2 diabetes were randomised to treatment with NovoMix 30 either alone or in combination with metformin, or to metformin together with sulfonylurea. The primary efficacy variable - HbA<sub>1c</sub> after 16&nbsp;weeks of treatment - did not differ between patients with NovoMix 30 combined with metformin and patients with metformin plus sulfonylurea. In this trial, 57% of the patients had baseline HbA<sub>1c</sub> above 9%; in these patients, treatment with NovoMix 30 in combination with metformin resulted in significantly lower HbA<sub>1c </sub>than metformin in combination with sulfonylurea.</p><p>&nbsp;</p><p>In one study, patients with type 2 diabetes, insufficiently controlled on oral hypoglycaemic agents alone, were randomised to treatment with twice daily NovoMix 30 (117&nbsp;patients) or once daily insulin glargine (116&nbsp;patients). After 28&nbsp;weeks of treatment following the dosing guideline outlined in section 4.2, the mean reduction in HbA<sub>1c</sub> was 2.8% with NovoMix 30 (mean at baseline&nbsp;=&nbsp;9.7%). With NovoMix 30, 66% and 42% of the patients reached HbA<sub>1c</sub> levels below 7% and 6.5%, respectively, and mean FPG was reduced by about 7&nbsp;mmol/l (from 14.0&nbsp;mmol/l at baseline to 7.1&nbsp;mmol/l).</p><p>&nbsp;</p><p>In patients with type 2 diabetes, a meta-analysis showed a reduced risk of overall nocturnal hypoglycaemic episodes and major hypoglycaemia with NovoMix 30 compared to biphasic human insulin 30. The risk of overall daytime hypoglycaemic episodes was increased in patients treated with NovoMix 30.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>&nbsp;</p><p>A 16-week clinical trial comparing postprandial glycaemic control of meal-related NovoMix 30 with meal-related human insulin/biphasic human insulin 30 and bedtime NPH insulin was performed in 167&nbsp;patients aged 10 to&nbsp;18&nbsp;years. Mean HbA<sub>1c</sub> remained similar to baseline throughout the trial in both treatment groups, and there was no difference in hypoglycaemia rate with NovoMix 30 or biphasic</p><p>human insulin 30.</p><p>In a smaller (54&nbsp;patients) and younger (age range 6 to&nbsp;12&nbsp;years) population, treated in a double-blind, cross-over trial (12&nbsp;weeks on each treatment), the rate of hypoglycaemic episodes and the postprandial glucose increase were significantly lower with NovoMix 30 compared to biphasic human insulin 30. Final HbA<sub>1c</sub> was significantly lower in the biphasic human insulin 30 treated group compared with NovoMix 30.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption, distribution and elimination</strong></p><p>&nbsp;</p><p>In insulin aspart, substitution of amino acid proline with aspartic acid at position B28 reduces the tendency to form hexamers as observed with soluble human insulin. The insulin aspart in the soluble phase of NovoMix 30 comprises 30% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin. The remaining 70% is in crystalline form as protamine-crystallised insulin aspart; this has a prolonged absorption profile similar to human NPH insulin.</p><p>&nbsp;</p><p>The maximum serum insulin concentration is, on average, 50% higher with NovoMix 30 than with biphasic human insulin 30. The time to maximum concentration is, on average, half of that for biphasic human insulin 30. In healthy volunteers, a mean maximum serum concentration of 140&nbsp;&plusmn;&nbsp;32&nbsp;pmol/l was reached about 60&nbsp;minutes after a subcutaneous dose of 0.20&nbsp;unit/kg body weight. The mean half life (t<sub>&frac12;</sub>) of NovoMix 30, reflecting the absorption rate of the protamine bound fraction, was about 8&ndash;9&nbsp;hours. Serum insulin levels returned to baseline 15&ndash;18&nbsp;hours after a subcutaneous dose. In type 2 diabetic patients, the maximum concentration was reached about 95&nbsp;minutes after dosing, and concentrations well above zero for not less than 14&nbsp;hours post-dosing were measured.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p>&nbsp;</p><p>The pharmacokinetics of NovoMix 30 have not been investigated in elderly patients or in patients with renal or hepatic impairment.</p><p><u>&nbsp;</u></p><p><em>Paediatric population</em></p><p>The<strong><em> </em></strong>pharmacokinetics<strong><em> </em></strong>of NovoMix 30 have not<strong><em> </em></strong>been investigated in<strong><em> </em></strong>children<strong><em> </em></strong>or<strong><em> </em></strong>adolescents. However, the pharmacokinetic and pharmacodynamic properties of soluble insulin aspart have been investigated in children (6&ndash;12&nbsp;years) and adolescents (13&ndash;17&nbsp;years) with type 1 diabetes. Insulin aspart was rapidly absorbed in both age groups, with similar t<sub>max</sub> as in adults. However, C<sub>max </sub>differed between the age groups, stressing the importance of the individual titration of insulin aspart.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development.</p><p>&nbsp;</p><p>In <em>in vitro</em> tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin. Studies also demonstrate that the dissociation of binding to the insulin receptor of insulin aspart is equivalent to human insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycerol</p><p>Phenol</p><p>Metacresol</p><p>Zinc chloride</p><p>Disodium phosphate dihydrate</p><p>Sodium chloride</p><p>Protamine sulfate</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Before opening: 2 years.
	
	During use or when carried as a spare: The product can be stored for a maximum of 4 weeks. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Before opening:</u> Store in a refrigerator (2&deg;C&ndash;8&deg;C). Keep away from the cooling element. Do not freeze.</p><p>&nbsp;</p><p><u>NovoMix 30 Penfill</u></p><p><u>During use or when carried as a spare:</u> Store below 30&deg;C. Do not refrigerate. Do not freeze.</p><p>Keep the cartridge in the outer carton in order to protect it from light.</p><p>&nbsp;</p><p><u>NovoMix 30 FlexPen</u></p><p><u>During use or when carried as a spare:</u> Store below 30&deg;C. Do not refrigerate. Do not freeze.</p><p>Keep the cap on FlexPen in order to protect it from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>NovoMix 30 Penfill</u></p><p>3&nbsp;ml suspension in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene). The cartridge contains a glass ball to facilitate resuspension.</p><p>&nbsp;</p><p>Pack sizes of 5 and 10&nbsp;cartridges. Not all pack sizes may be marketed.</p><p><u>&nbsp;</u></p><p><u>NovoMix 30 FlexPen</u></p><p>3&nbsp;ml suspension in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene. The cartridge contains a glass ball to facilitate resuspension.</p><p>&nbsp;</p><p>Pack sizes of 1&nbsp;(with or without needles), 5&nbsp;(without needles) and 10&nbsp;(without needles)&nbsp;pre-filled pens. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After removing NovoMix 30 Penfill or NovoMix 30 FlexPen from the refrigerator, it is recommended to allow NovoMix 30 Penfill or NovoMix 30 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.</p><p>&nbsp;</p><p>Do not use this medicinal product if you notice that the resuspended liquid is not uniformly white, cloudy and aqueous.</p><p>The necessity of resuspending the NovoMix 30 suspension immediately before use is to be stressed to the patient.</p><p>NovoMix 30 which has been frozen must not be used.</p><p>&nbsp;</p><p>The patient should be advised to discard the needle after each injection.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Needles, cartridges and pre-filled pens must not be shared.</p><p>&nbsp;</p><p>The cartridge must not be refilled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Novo Nordisk A/S
	Novo Allé
	DK-2880 Bagsværd
	Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Aug-2020

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>